RadioMedix, Inc. is a clinical-stage biotechnology company structured around innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and targeted therapy using alpha and beta-emitters). RadioMedix has established contract service facilities for academic and industrial partners: cGMP manufacturing and analytical sites for human clinical trials; the commercial phase manufacturing site for scaled-up production of radiopharmaceuticals; and also Drug discovery facility with small animal Molecular Imaging Center for the pre-clinical evaluation of new targets in vitro and in vivo. In October 2019 it was announced that Novigenix SA, a leading Immuno-Transcriptomics company developing early cancer detection and precision medicine, would collaborate RadioMedix Inc. to develop a precision diagnostic test based on Novigenixs technology that is designed to measure response in patients with neuroendocrine tumors (NET) treated with Alpha and Beta Peptide Receptor Radionuclide Therapy (PRRT).
